Projects

“Reproductive and regenerative medicine - research into new platforms and potential”

Cerm

Program

Top research of Scientific Centres of Excellence (KK.01.1.1.01)

Duration

72 Months (01/11/2017 – 01/11/2022)

Location

Zagreb, Croatia

Project funding

5.050.357,52 €

Project goals

The scientific Center of Excellence for Reproductive and Regenerative Medicine (CERRM) was established by merging two project applications from the University of Zagreb School of Medicine (UZSM) in the call for proposals for the establishment of the Croatian scientific centres of excellence in 2013. CERRM has been awarded by decision of the Ministry of Science, Education and Sport (MSES) and it includes two research units:


  • Biomedical research on reproduction and development, coordinated by Professor Davor Ježek, PhD, MD
  • Regenerative medicine, coordinated by Professor Slobodan Vukicevic, PhD, MD

The Head of CERRM alternates annually, and the position is currently held by Professor Vukicevic.

Unit for Regenerative Medicine (RM) integrates research groups from basic science, clinics, education and industry, forming a multidisciplinary environment which facilitates the implementation of translational research. By creating new technologies and biological treatments thus augmenting the efficacy and safety of regenerative medicine, RM aims to improve human health and increase the quality of life.


Genera Research is one of nine partner institutions in the Research Unit for Regenerative Medicine with its core activities on the project:


  • GLP and GMP production of recombinant proteins (BMP1 isoforms, BMP6, etc.)
  • Development of new research tools
  • Bioassay development

Project results

New formulations of the drug OSTEOGROW were tested, which in addition to the patient's autologous blood coagulum and rhBMP6, it also contains extracellular matrix resistant to compression (CRM; compression resistant matrix) in spinal models rabbit and sheep fusions; obtaining new global patents for the commercial exploitation of new drug formulations Osteogrow by 2043 in USA, EU, Canada, Australia, China, Japan and India. Discovery of the mechanism antifibrotic effect of BMP1.3 isoform inhibition in models of chronic fibrosis of rodent organs and publications results in journals of the "Nature" group.